Mosaic Clinical Technologies' Cognita CXR, an AI model for chest x-ray interpretation, has received breakthrough device designation from the U.S. Food and Drug Administration (FDA).
The software analyzes chest x-rays and generates preliminary findings that licensed radiologists review and finalize, according to the company. Internal clinical validation showed that radiologists using Cognita CXR achieved enhanced detection ranging from 16% to 65% for certain findings and an 18% boost in average interpretation efficiency, Mosaic said.
Cognita operates as the AI business unit of Mosaic Clinical Technologies, a subsidiary of Radiology Partners.
